Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5- carbonitrile) analogues at monoamine transporters

Journal of Medicinal Chemistry

Volumn 53, Issue 16, 2010, Pages 6112-6121

  Zhang, Peng ^a   Cyriac, George ^a   Kopajtic, Theresa ^a   Zhao, Yongfang ^b   Javitch, Jonathan A ^b   Katz, Jonathan L ^a   Newman, Amy Hauck ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (4 FLUOROPHENYL) 4 PHENYL 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [1 (4 FLUOROPHENYL) 4 STYRYL 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [1 (4 FLUOROPHENYL) 5 (3' METHOXYPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [1 (4 FLUOROPHENYL) 5 IODO 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [1 (4 FLUOROPHENYL) 5 PHENETHYL 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [1 (4 FLUOROPHENYL) 5 PHENYL 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [1 (4 FLUOROPHENYL) 5 STYRYL 1,3 DIHYDROISOBENZOFURAN 1 YL) N,N DIMETHYLPROPAN 1 AMINE; 3 [4 BROMO 1 (4 FLUOROPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [5 (3 AMINO PHENYL) 1 (4 FLUOROPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [5 (3 CHLOROPHENYL) 1 (4 FLUOROPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [5 (3 FLUOROPHENYL) 1 (4 FLUOROPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [5 (3' CYANO PHENYL) 1 (4 FLUOROPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [5 (3,4 DICHLOROPHENYL) 1 (4 FLUOROPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [5 (3,5 DIFLUOROPHENYL) 1 (4 FLUOROPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE OXALATE; 3 [5 (4 CHLOROSTYRYL) 1 (4 FLUOROPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 3 [5 BROMO 1 (4 FLUOROPHENYL) 1,3 DIHYDROISOBENZOFURAN 1 YL] N,N DIMETHYLPROPAN 1 AMINE; 4 [4 (DIMETHYLAMINO) 1 (4 FLUOROPHENYL) 1 HYDROXYBUTYL] 3 (HYDROXYMETHYL) BENZOBROMIDE; 4 [4 (DIMETHYLAMINO) 1 (4 FLUOROPHENYL) 1 HYDROXYBUTYL] 3 (HYDROXYMETHYL) BENZONITRILE; 6 BROMO PHTHALIDE; CITALOPRAM; DOPAMINE TRANSPORTER; ESCITALOPRAM; METHYL 3 BROMO 2 METHYLBENZOATE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG BINDING; DRUG DESIGN; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENANTIOSELECTIVITY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

AMINO ACID TRANSPORT SYSTEMS; ANIMALS; BACTERIAL PROTEINS; BINDING, COMPETITIVE; BRAIN; CITALOPRAM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; LEUCINE; LIGANDS; MODELS, MOLECULAR; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955855315     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1005034     Document Type: Article

References (40)

1. Butler, S. G.; Meegan, M. J. Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter Curr. Med. Chem. 2008, 15 (17) 1737-1761
2. Waugh, J.; Goa, K. L. Escitalopram: a review of its use in the management of major depressive and anxiety disorders CNS Drugs 2003, 17 (5) 343-362
3. Yamashita, A.; Singh, S. K.; Kawate, T.; Jin, Y.; Gouaux, E. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters Nature 2005, 437 (7056) 215-223
4. Xhaard, H.; Backstrom, V.; Denessiouk, K.; Johnson, M. S. Coordination of Na(+) by monoamine ligands in dopamine, norepinephrine, and serotonin transporters J. Chem. Inf. Model. 2008, 48 (7) 1423-1437
5. Sinning, S.; Musgaard, M.; Jensen, M.; Severinsen, K.; Celik, L.; Koldso, H.; Meyer, T.; Bols, M.; Jensen, H. H.; Schiott, B.; Wiborg, O. Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter J. Biol. Chem. 2010, 285 (11) 8363-8374
6. Shi, L.; Quick, M.; Zhao, Y.; Weinstein, H.; Javitch, J. A. The mechanism of a neurotransmitter:sodium symporter - inward release of Na+ and substrate is triggered by substrate in a second binding site Mol. Cell 2008, 30 (6) 667-677
7. Indarte, M.; Madura, J. D.; Surratt, C. K. Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template Proteins 2008, 70 (3) 1033-1046
8. Zhou, Z.; Zhen, J.; Karpowich, N. K.; Law, C. J.; Reith, M. E.; Wang, D. N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures Nat. Struct. Mol. Biol. 2009, 16 (6) 652-657
9. Wang, C. I.; Lewis, R. J. Emerging structure-function relationships defining monoamine NSS transporter substrate and ligand affinity Biochem. Pharmacol. 2009, 79 (8) 1083-1091
10. Ravna, A. W.; Sylte, I.; Dahl, S. G. Structure and localisation of drug binding sites on neurotransmitter transporters J. Mol. Model. 2009, 15 (10) 1155-1164
11. Quick, M.; Winther, A. M.; Shi, L.; Nissen, P.; Weinstein, H.; Javitch, J. A. Binding of an octylglucoside detergent molecule in the second substrate (S2) site of LeuT establishes an inhibitor-bound conformation Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (14) 5563-5568
12. Kaufmann, K. W.; Dawson, E. S.; Henry, L. K.; Field, J. R.; Blakely, R. D.; Meiler, J. Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies Proteins 2009, 74 (3) 630-642
13. Andersen, J.; Taboureau, O.; Hansen, K. B.; Olsen, L.; Egebjerg, J.; Stromgaard, K.; Kristensen, A. S. Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants J. Biol. Chem. 2009, 284 (15) 10276-10284
14. Singh, S. K. LeuT: A prokaryotic stepping stone on the way to a eukaryotic neurotransmitter transporter structure Channels (Austin) 2008, 2 (5) 380-389
15. Celik, L.; Sinning, S.; Severinsen, K.; Hansen, C. G.; Moller, M. S.; Bols, M.; Wiborg, O.; Schiott, B. Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation J. Am. Chem. Soc. 2008, 130 (12) 3853-3865
16. Beuming, T.; Kniazeff, J.; Bergmann, M. L.; Shi, L.; Gracia, L.; Raniszewska, K.; Newman, A. H.; Javitch, J. A.; Weinstein, H.; Gether, U.; Loland, C. J. The binding sites for cocaine and dopamine in the dopamine transporter overlap Nat. Neurosci. 2008, 11 (7) 780-789
17. Zhou, Z.; Zhen, J.; Karpowich, N. K.; Goetz, R. M.; Law, C. J.; Reith, M. E.; Wang, D. N. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake Science 2007, 317 (5843) 1390-1393
18. Singh, S. K.; Yamashita, A.; Gouaux, E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters Nature 2007, 448 (7156) 952-956
19. Jorgensen, A. M.; Tagmose, L.; Jorgensen, A. M.; Bogeso, K. P.; Peters, G. H. Molecular dynamics simulations of Na+/Cl(-)-dependent neurotransmitter transporters in a membrane-aqueous system ChemMedChem 2007, 2 (6) 827-840
20. Jorgensen, A. M.; Tagmose, L.; Jorgensen, A. M.; Topiol, S.; Sabio, M.; Gundertofte, K.; Bogeso, K. P.; Peters, G. H. Homology modeling of the serotonin transporter: insights into the primary escitalopram-binding site ChemMedChem 2007, 2 (6) 815-826
21. Celik, L.; Schiott, B.; Tajkhorshid, E. Substrate binding and formation of an occluded state in the leucine transporter Biophys. J. 2008, 94 (5) 1600-1612
22. Plenge, P.; Gether, U.; Rasmussen, S. G. Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites Eur. J. Pharmacol. 2007, 567 (1-2) 1-9
23. Singh, S. K.; Piscitelli, C. L.; Yamashita, A.; Gouaux, E. A competitive inhibitor traps LeuT in an open-to-out conformation Science 2008, 322 (5908) 1655-1661
24. Koldso, H.; Severinsen, K.; Tran, T. T.; Celik, L.; Jensen, H. H.; Wiborg, O.; Schiott, B.; Sinning, S. The two enantiomers of citalopram bind to the human serotonin transporter in reversed orientations J. Am. Chem. Soc. 2010, 132 (4) 1311-1322
25. Andersen, J.; Olsen, L.; Hansen, K. B.; Taboureau, O.; Jorgensen, F. S.; Jorgensen, A. M.; Bang-Andersen, B.; Egebjerg, J.; Stromgaard, K.; Kristensen, A. S. Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter J. Biol. Chem. 2010, 285 (3) 2051-2063
26. Sanchez, C.; Bogeso, K. P.; Ebert, B.; Reines, E. H.; Braestrup, C. Escitalopram versus citalopram: the surprising role of the R-enantiomer Psychopharmacology (Berlin) 2004, 174 (2) 163-176
27. Sanchez, C.; Bergqvist, P. B.; Brennum, L. T.; Gupta, S.; Hogg, S.; Larsen, A.; Wiborg, O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities Psychopharmacology (Berlin) 2003, 167 (4) 353-362
28. Henry, L. K.; Field, J. R.; Adkins, E. M.; Parnas, M. L.; Vaughan, R. A.; Zou, M. F.; Newman, A. H.; Blakely, R. D. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants J. Biol. Chem. 2006, 281 (4) 2012-2023
29. Sanchez, C.; Kreilgaard, M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram Pharmacol., Biochem. Behav. 2004, 77 (2) 391-398
30. Storustovu, S.; Sanchez, C.; Porzgen, P.; Brennum, L. T.; Larsen, A. K.; Pulis, M.; Ebert, B. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter Br. J. Pharmacol. 2004, 142 (1) 172-180
31. Kasper, S.; Sacher, J.; Klein, N.; Mossaheb, N.; Attarbaschi-Steiner, T.; Lanzenberger, R.; Spindelegger, C.; Asenbaum, S.; Holik, A.; Dudczak, R. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram Int. Clin. Psychopharmacol. 2009, 24 (3) 119-125
32. Bigler, A. J.; Bogeso, K. P.; Toft, A.; Hansed, V. Quantitative structure-activity relationships in a series of selective 5-HT uptake inhibitors Eur. J. Med. Chem.-Chim. Ther. 1977, 12 (3) 289-295
33. Eildal, J. N.; Andersen, J.; Kristensen, A. S.; Jorgensen, A. M.; Bang-Andersen, B.; Jorgensen, M.; Stromgaard, K. From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies J. Med. Chem. 2008, 51 (10) 3045-3048
34. Xiao, X.; Antony, S.; Pommier, Y.; Cushman, M. Total synthesis and biological evaluation of 22-hydroxyacuminatine J. Med. Chem. 2006, 49 (4) 1408-1412
35. Nannapaneni, V. C. Processes for the preparation of escitalopram and its precursor. WO 2004/065375 A1, 2004.
36. Xu, L.; Izenwasser, S.; Katz, J. L.; Kopajtic, T.; Klein-Stevens, C.; Zhu, N.; Lomenzo, S. A.; Winfield, L.; Trudell, M. L. Synthesis and biological evaluation of 2-substituted 3beta-tolyltropane derivatives at dopamine, serotonin, and norepinephrine transporters J. Med. Chem. 2002, 45 (6) 1203-1210
37. Kumar, N.; Nayyar, S.; Gupata, M. Processes for the preparation of citalopram and its intermediate from 5-aminophthalide. WO 2006/103550 A1, 2006.
38. MacroModel; Maestro using the default setting of command "flexible ligand alignment". 9.6; 8.5; Schrödinger, LLC.: New York, 2008.
39. Jorgensen, A. M.; Topiol, S. Driving Forces for Ligand Migration in the Leucine Transporter Chem. Biol. Drug Des. 2008, 72, 265-277
40. El-Gindy, A.; Emara, S.; Mesbah, M. K.; Hadad, G. M. Liquid chromatography determination of citalopram enantiomers using beta-cyclodextrin as a chiral mobile phase additive J. AOAC Int. 2006, 89 (1) 65-70